canal-based glaucoma surgery

ASX biotechs finally getting some love

Leave a Comment
ASX biotechs finally getting some love

There are clear signs the biotech sector is springing back to life after a disappointing 2022. These ASX stocks have shone in the past month. The benchmark US Biotech ETF index, also known as the XBI, has quietly risen by 3 per cent over the past six months. In Australia, the S&P/ASX 200 Health Care … [Read more…]

Salter Brothers eyeing small cap medtechs

Leave a Comment
Salter Brothers eyeing small cap medtechs

Salter Brothers – which specialises in alternative assets – sees great potential in these three ASX-based medtechs, both for patients and investors. Today we hear from Salter Brothers director of equities and portfolio manager Gregg Taylor. Firstly a little bit about Salter Brothers, which is a $3 billion alternative asset manager in Australia. The fund … [Read more…]